SYNDIVIA
Syndivia is a biotechnology company. Syndivia's vision is to deliver the best treatment to cancer patients by harnessing unique properties of tumour hallmarks and microenvironment.
SYNDIVIA
Industry:
Biotechnology Health Care Medical
Founded:
2014-01-01
Address:
Illkirch, Alsace, France
Country:
France
Website Url:
http://www.syndivia.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
3.05 M EUR
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Google Tag Manager Google Analytics Content Delivery Network LetsEncrypt SSL By Default Font Awesome
Similar Organizations
Atugen
A biotechnology company based in Berlin, Germany.
Boditech Med
Boditech Med is a biotechnology company based in Chuncheon.
Cellectis
Cellartis AB is a biotechnology company based in Sweden.
fasteris
Fasteris is a Swiss biotechnology company based in Geneva.
Geneius
Geneius is a Biotechnology company.
Mucosis
Mucosis is a clinical stage Dutch biotechnology company developing mucosal vaccines.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Current Employees Featured
Founder
Investors List
Bpifrance
Bpifrance investment in Venture Round - Syndivia
Cap Innov'Est
Cap Innov'Est investment in Seed Round - Syndivia
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - Syndivia
Official Site Inspections
http://www.syndivia.com Semrush global rank: 1.94 M Semrush visits lastest month: 11.04 K
- Host name: 198.49.23.145
- IP address: 198.49.23.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Syndivia"
Syndivia - Crunchbase Company Profile & Funding
Organization. Syndivia . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Syndivia is a biotechnology company based in โฆSee details»
About - Syndivia
©[YEAR] Syndivia, 8 Allée Gaspard Monge, ISIS, Strasbourg, Grand Est, 67083, France [email protected] [email protected]See details»
Syndivia Overview | SignalHire Company Profile
Syndivia is a private company that has been in the industry for 10 years. The company currently specializes in the Biotechnology, Biotechnology areas. The position of the Co-Founder & CEO โฆSee details»
Syndivia Company Profile 2024: Valuation, Funding & Investors
When was Syndivia founded? Syndivia was founded in 2014. Where is Syndivia headquartered? Syndivia is headquartered in Strasbourg, France. What is the size of Syndivia? Syndivia has 6 โฆSee details»
Syndivia - euroquity.com
About your organization Syndivia is a biotechnology company focused on the development of next-generation targeted therapies for cancer treatment. The company unites leading experts โฆSee details»
Syndivia - Funding, Financials, Valuation & Investors - Crunchbase
Syndivia is a biotechnology company based in France. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. Log In. Organization. โฆSee details»
Syndivia Company Profile - Office Locations, Competitors ... - Craft
Syndivia is a biotechnology company that develops treatment solutions to cancer patients by leveraging microenvironment and anatomical hallmarks for tumors. It provides APN technology โฆSee details»
Syndivia - Products, Competitors, Financials, Employees, โฆ
Syndivia focuses on the development of targeted antibody-drug conjugates (ADCs) with a drug-to-antibody ratio of 1 (DAR1) for the treatment of solid tumors. Use the CB Insights Platform to โฆSee details»
SYNDIVIA Company Profile | STRASBOURG, GRAND EST, France
Find company research, competitor information, contact details & financial data for SYNDIVIA of STRASBOURG, GRAND EST. Get the latest business insights from Dun & Bradstreet.See details»
Syndivia - Overview, News & Competitors | ZoomInfo.com
Syndivia's mission is to develop new therapies for p atients with the most difficult-to-treat cancer indications. Read More. View Company Info for Free. Who is Syndivia. Headquarters. 8 Allée โฆSee details»
Syndivia - Contacts, Employees, Board Members, Advisors & Alumni
Syndivia is a biotechnology company based in France. Start Free Trial . Chrome ExtensionSee details»
SYNDIVIA - VentureRadar
Syndivia is a biotechnology company that is developing a pipeline of targeted therapies for solid cancers by leveraging a specific targeting of the tumor microenvironment and anatomical โฆSee details»
Syndivia - Company Profile & Staff Directory - ContactOut
Syndivia's vision is to deliver the best treatment to cancer patients by harnessing unique properties of tumour hallmarks and microenvironment. Product OverviewSee details»
Syndivia - Company Profile - Tracxn
Oct 30, 2024 Syndivia ranks 1,014th among 4451 active competitors. 1351 of its competitors are funded while 910 have exited. Overall, Syndivia and its competitors have raised over $96.5B in โฆSee details»
News - Syndivia
Nov 16, 2023 News & Press Archive. STRASBOURG, France, March 10, 2020 โ Syndivia, a research-driven biotechnology company focused on the development of new therapeutic โฆSee details»
La médecine du futur (4/5) : Syndivia, la bête de concours qui veut ...
Syndivia, la société qu'il vient de créer à Strasbourg, est entrée en négociation avec un groupe pharmaceutique français pour un projet de co-développement d'une nouvelle thérapie.See details»
Vision - Syndivia
At Syndivia, we are dedicated to advancing treatment options for cancer patients through our innovative GeminiMabโข Technology. This platform enables the creation of site-specific โฆSee details»
PRESS RELEASE Syndivia In-Licenses DARx Technology for 1-to-1 โฆ
* Organization for accelerating tech transfer About Syndivia Syndivia is a research-driven biotechnology company that is developing a pipeline of targeted therapies for solid cancers by โฆSee details»
Pipeline - Syndivia
2017: Out-licensing agreement established with Inatherys, limited to one target (CD71). The ADC is currently undergoing phase I/IIa clinical trial (NCT03957915). 2022: Auricula Biosciences co โฆSee details»